Juan Valle, Chief Medical Officer at Cholangiocarcinoma Foundation, shared a post on LinkedIn:
“I’m encouraged to see the announcement that the FDA has granted Breakthrough Therapy designation to zenocutuzumab-zbco for adults with advanced unresectable or metastatic cholangiocarcinoma harboring an NRG1 gene fusion.
This rare genomic alteration represents an actionable target in a cancer with very limited treatment options. The eNRGy Phase 2 trial results are promising and reinforce the importance of comprehensive molecular testing—particularly tissue-based RNA next generation sequencing (NGS) – to ensure that patients with rare drivers such as NRG1 fusions are identified and have the opportunity to access targeted therapies.
For patients with cholangiocarcinoma, progress like this offers much-needed hope and highlights the vital role of precision oncology in shaping the future of care.
Learn more about the eNRGy trial and zenocutuzumab-zbco.”
You can also read: FDA Grants Breakthrough Therapy Designation to Zenocutuzumab-zbco for NRG1-Positive Cholangiocarcinoma
